Laboratory services
Search documents
Labcorp to Announce First Quarter Financial Results on April 30, 2026
Prnewswire· 2026-03-31 20:15
<!doctype html> <!-- For structured data --> <!-- For language declaration --> Labcorp to Announce First Quarter Financial Results on April 30, 2026 <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationBURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026. The company wi ...
Is IDEXX Laboratories Stock Outperforming the S&P 500?
Yahoo Finance· 2026-03-16 08:19
Company Overview - IDEXX Laboratories, Inc. is a leader in veterinary diagnostics, software, and water testing solutions, based in Westbrook, Maine, with a market cap of $45.7 billion [1] - The company develops diagnostic instruments, test kits, software, and laboratory services for veterinarians, farmers, and laboratories to monitor animal health and detect diseases [1] Market Position - IDEXX is classified as a "large-cap stock" and is recognized as a market leader in veterinary diagnostics, benefiting from strong brand recognition and a large installed base of diagnostic instruments [2] - The company's solutions are utilized in over 175 countries, indicating a robust global presence [2] Stock Performance - Shares of IDEXX have decreased by 25.5% from their 52-week high of $769.98 and have dipped 18.5% over the past three months, underperforming the S&P 500 Index's decline of 2.9% [3] - Over the past six months, IDEXX shares are down 10.5%, while the S&P 500 has shown marginal returns [5] - Despite recent declines, IDEXX stock has increased by 41.2% over the past 52 weeks, outperforming the S&P 500's 20.1% increase during the same period [5] Recent Financial Performance - On February 2, IDEXX reported a strong fourth-quarter 2025 performance with revenue of $1.1 billion and adjusted earnings of $3.08 per share, both exceeding analyst expectations [6] - However, the gross margin of 60.3% fell short of the consensus forecast of 61% [6] Competitive Landscape - IDEXX has outperformed its main competitor, Zoetis Inc., which has seen a decline of 27.8% over the past 52 weeks and 22% over the past six months [7] - Analysts maintain a cautiously optimistic outlook for IDEXX, with a consensus rating of "Moderate Buy" and a mean price target of $773.58, representing a 34.8% premium to current levels [7]
Core Labs Jumps 79% in 6 Months: Time to Buy or Stay on the Sidelines?
ZACKS· 2026-02-18 14:40
Core Insights - Core Laboratories Inc. (CLB) has experienced significant stock performance, gaining approximately 78.8% over the past six months, outperforming its Oil & Gas Field Services sub-industry and the broader Oil & Energy sector [3][5] - The company generates revenue through laboratory services, equipment sales, and data analytics, focusing on reservoir optimization and enhanced oil recovery [2][6] Revenue Growth - CLB's fourth-quarter 2025 revenues reached $138.3 million, reflecting a 3% sequential increase and a 7% year-over-year rise, driven by strong international demand for its proprietary technologies [6][7] - The company has demonstrated a consistent return of capital to shareholders, repurchasing 363,207 shares for $5.7 million in Q4 2025 and a total of 1.2 million shares for the full year [7][8] Financial Health - CLB has reduced its net debt by $18.7 million in 2025, with a cumulative reduction of $205.8 million (approximately 70%) since late 2019, improving its leverage ratio to 1.09, the lowest in nine years [9][10] - The asset-light business model has allowed CLB to generate $26 million in free cash flow for the full year 2025, with capital expenditures expected to remain low relative to revenues [10] Market Challenges - The company anticipates a decline in U.S. land completion activity in the first half of 2026 compared to the same period in 2025, which may impact its Production Enhancement segment [11] - Margin compression is expected due to rising costs of imported raw materials subject to tariffs, potentially affecting profitability by approximately 2-3 cents per quarter [12] - CLB's revenue from long-cycle international projects is dependent on clients' geologic success rates, which can lead to variability in performance [13] Valuation Concerns - CLB's P/E ratio stands at 21.83, slightly above the sub-industry average of 21.6, indicating a premium valuation that may pose risks if growth expectations are not met [14]
Labcorp Announces 2025 Fourth Quarter and Full Year Results
Prnewswire· 2026-02-17 11:50
Core Insights - Labcorp reported strong financial performance for Q4 2025 and the full year, with revenue growth of over 7% and double-digit adjusted EPS growth, driven by its Diagnostics and Central Laboratory businesses [1][2] - The company provided guidance for 2026, projecting revenue between $14.61 billion and $14.79 billion, adjusted EPS between $17.55 and $18.25, and free cash flow of $1.24 billion to $1.36 billion [1][2] Financial Performance - Q4 2025 revenue was $3.52 billion, a 5.6% increase from Q4 2024's $3.33 billion; full-year revenue reached $13.95 billion, up 7.2% from $13.01 billion [1][2] - Adjusted EPS for Q4 was $4.07, compared to $3.45 in Q4 2024; full-year adjusted EPS was $16.44, up from $14.57 [1][2] - Free cash flow for Q4 was $490.3 million, down from $665.1 million in Q4 2024; full-year free cash flow increased to $1.21 billion from $1.10 billion [1][2] Strategic Developments - Labcorp completed several acquisitions, including assets from Empire City Laboratories, Incyte Diagnostics, and Community Health Systems, enhancing its service offerings [1][2] - The company announced plans to build a new 500,000 square foot Central Laboratory facility in Indiana, expected to begin construction in late 2026 [1][2] - Labcorp launched new consumer-initiated tests and expanded access to molecular residual disease testing for various cancers, as well as the first FDA-cleared blood test for Alzheimer's disease [1][2] Capital Allocation - In 2025, Labcorp invested $582 million in acquisitions, paid $240.7 million in dividends, and repurchased $450 million of its stock [1][2] - The company reported a cash and cash equivalents balance of $532.3 million and total debt of $5.58 billion at the end of Q4 2025 [1][2] Segment Performance - The Diagnostics Laboratories segment generated $2.73 billion in revenue for Q4 2025, a 5.5% increase from Q4 2024; adjusted operating income was $419.2 million, with a margin of 15.4% [2][4] - The Biopharma Laboratory Services segment reported $793 million in revenue for Q4 2025, a 3.4% increase, with adjusted operating income of $136.1 million and a margin of 17.2% [2][4]
ICON Public Limited Company (ICLR) Delays Earnings Amid Internal Investigation
Yahoo Finance· 2026-02-14 13:17
Core Viewpoint - ICON Public Limited Company is currently facing an internal investigation into its revenue recognition practices, which has led to a delay in earnings reports and the withdrawal of its 2025 financial guidance [3][4][7]. Group 1: Internal Investigation - The Audit Committee of ICON initiated an internal investigation in late October 2025 regarding certain accounting practices and controls after concerns were raised by company management [5]. - The investigation is being conducted by outside legal counsel with support from forensic and technical accounting firms [5]. - Preliminary findings suggest that ICON's reported revenue for 2023 and 2024 may have been overstated by less than 2% in each fiscal year [6]. Group 2: Financial Impact - Due to the ongoing investigation, ICON has delayed the release of its fourth quarter and full year 2025 earnings results, now expected on or before April 30, 2026 [4]. - The company has withdrawn its previously issued full year 2025 financial guidance and is unable to communicate its 2025 financial performance at this time [7]. - TD Cowen estimates the impact of the investigation on adjusted EPS to be about 13% for 2023 and 12% for 2024 [3]. Group 3: Market Reaction - Following the announcement of the investigation, ICON's share price dropped by 35%, which analysts believe may be an overreaction [3].
Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026
Prnewswire· 2026-01-15 21:15
Core Viewpoint - Labcorp Holdings Inc. will release its financial results for Q4 2025 on February 17, 2026, before market opening, followed by a conference call at 9 a.m. ET to discuss the results [1]. Group 1: Financial Results Announcement - The financial results for Q4 2025 will be released before the market opens on February 17, 2026 [1]. - A conference call and webcast will take place at 9 a.m. ET on the same day to discuss the financial results [1]. Group 2: Webcast and Participation - The conference call will be available via live webcast on the Labcorp Investor Relations website, with participants encouraged to join 10 minutes early [2]. - A replay of the webcast will be accessible approximately two hours after the live event and will remain available until February 4, 2027 [3]. Group 3: Company Overview - Labcorp is a global leader in laboratory services, aiding healthcare professionals and researchers in decision-making [4]. - The company employs nearly 70,000 individuals and operates in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [4]. - Labcorp conducts more than 700 million tests annually for patients worldwide [4].
Is Charles River Laboratories Stock Underperforming the Dow?
Yahoo Finance· 2025-12-16 10:24
Core Insights - Charles River Laboratories International, Inc. (CRL) is a leading American contract research organization (CRO) with a market cap of $9.5 billion, serving various sectors including pharmaceuticals and biotechnology [1] - CRL is categorized as a mid-cap stock, benefiting from strong competitive advantages such as end-to-end preclinical drug development capabilities and long-standing client relationships [2] - The stock has shown significant short-term performance, gaining 30.2% over the past three months, outperforming the Dow Jones Industrial Average [3] Performance Metrics - CRL reached a 52-week high of $200.58, but on a year-to-date basis, it is up only 7.3%, lagging behind the Dow's 13.8% rise in 2025 [3][4] - The stock has maintained a position above its 50-day and 200-day moving averages since late September, indicating a strengthening technical uptrend [4] - Following an upgrade from JPMorgan Chase & Co., CRL shares gained over 2%, with the price target raised to $190, reflecting optimism about the company's fundamentals [5] Competitive Position - Compared to its peer Labcorp Holdings Inc., CRL has underperformed, with Labcorp showing a 14.8% increase year-to-date and 13.5% over the past 52 weeks [6]
Why a $5 Million Bet on Azenta Could Pay Off After a 70% Stock Slide
The Motley Fool· 2025-12-08 10:00
Company Overview - Azenta, Inc. is a leading provider of sample management and laboratory solutions for the global life sciences industry, leveraging advanced automation and integrated service offerings to support research, drug development, and biobanking initiatives [6] - The company has a market capitalization of $1.6 billion, with a revenue of $593.8 million and a net income of $23.7 million for the trailing twelve months [4] Recent Developments - Meros Investment Management disclosed a new position in Azenta, acquiring 159,945 shares valued at approximately $4.6 million, representing 2% of the fund's $234.2 million in reportable U.S. equity holdings [2][10] - Azenta's shares are currently priced at $35.05, reflecting a 22% decline over the past year, significantly underperforming the S&P 500, which increased by 13% during the same period [3] Financial Performance - The company reported a 310-basis-point increase in adjusted EBITDA margin, with an additional 300 basis points of margin expansion expected for the next fiscal year, indicating a potential profitability reset [9] - Fourth-quarter organic growth was driven by an 11% surge in Multiomics, and adjusted EBITDA rose 29% year over year, suggesting improving fundamentals [10] Business Model - Azenta generates revenue through sales of life science products and recurring service contracts, including sample storage, genomic sequencing, and laboratory analysis, serving pharmaceutical and biotechnology companies, biorepositories, and research institutes across various regions [8]
Surgery Partners, Inc. (NASDAQ: SGRY) Sees Varied Analyst Ratings Amidst Trading Fluctuations
Financial Modeling Prep· 2025-11-18 01:03
Company Overview - Surgery Partners, Inc. (NASDAQ:SGRY) operates surgical facilities across the United States, providing outpatient surgery, diagnostic imaging, and laboratory services, focusing on cost-effective surgical solutions [1] Price Targets and Analyst Ratings - Mizuho Securities set a price target of $22 for SGRY, indicating a potential upside of 44.74% from its current trading price of $15.20 [2] - Cantor Fitzgerald maintains an "overweight" rating with a price target of $36, while the Royal Bank of Canada has set a $31 target with an "outperform" rating [3] - Benchmark adjusted its price target for SGRY from $35 to $30, maintaining a "buy" rating, whereas Weiss Ratings reaffirmed a "sell (d-)" rating [4] Stock Performance and Trading Activity - SGRY's stock price has decreased to $15.06, a drop of 1.47% or $0.22, with fluctuations between $15.01 and $15.57 [2] - The stock has experienced a 52-week high of $26.16 and a low of $15.01, indicating its volatile nature [5] - There has been a significant surge in options trading activity, with a 498% increase in put options, suggesting investor uncertainty or hedging strategies [3][6] Market Capitalization and Trading Volume - The stock's market capitalization is approximately $1.95 billion, with a trading volume of 1,356,144 shares on the NASDAQ exchange [4]
Labcorp to Announce Third Quarter Financial Results on October 28, 2025
Prnewswire· 2025-09-25 20:15
Core Insights - Labcorp Holdings Inc. will release its financial results for Q3 2025 on October 28, 2025, before market opening [1] - A conference call and webcast will be held at 9 a.m. ET on the same day to discuss the results [1][2] - The earnings press release and financial information will be available on the Labcorp Investor Relations website [1] Company Overview - Labcorp is a global leader in laboratory services, providing innovative and comprehensive solutions to healthcare providers, pharmaceutical companies, and researchers [4] - The company employs nearly 70,000 individuals and operates in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [4] - Labcorp performs more than 700 million tests annually for patients worldwide [4]